A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811) is a research paper published in Clinical Lung Cancer (2021). On theSindex it has a DataRank of 0.494. It has been cited 26 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.494
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA062203
NCI NIH HHS
Grant: P30 CA093373
NCI NIH HHS
Grant: U10 CA046282
NCI NIH HHS
Grant: U10 CA180819
NCI NIH HHS
Grant: UG1 CA189830
NCI NIH HHS
Grant: UG1 CA189861
NCI NIH HHS
Grant: U10 CA180858
NCI NIH HHS
Grant: N01 CA013612
NCI NIH HHS
Grant: U10 CA013612
NCI NIH HHS
Grant: UG1 CA189858
NCI NIH HHS
Grant: U10 CA046368
NCI NIH HHS
Grant: U10 CA180846
NCI NIH HHS
Grant: U10 CA180888
NCATS NIH HHS
Grant: UL1 TR001863
NCI NIH HHS
Grant: U10 CA180826
NCI NIH HHS
Grant: UG1 CA233340
NCI NIH HHS
Grant: UG1 CA189957
NCI
FWCI
1.30
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals